US STOCK
ALNY Stock Analysis
US stocks · market data · technical indicators
Alnylam Pharmaceuticals, Inc.
ALNYUS stocksQuote delayed 15 min
10/26 上午10:33 updated
$224.03
-3.25-1.43%
Open
$227.28
High
$229.39
Low
$222.00
Volume
105.64萬
ALNY price history
-12.27%Open
255.36
Latest
224.03
High
255.36
Low
219.72
Average
230.70
Advertisement
Financial snapshot
ALNY - Alnylam Pharmaceuticals, Inc.
EPS
5.93USD
Forward EPS
12.35USD
P/E
37.78x
Forward P/E
18.14x
P/B
22.13x
ROE
96.56%
ROA
12.34%
Operating margin
17.93%
Profit margin
16.13%
Revenue growth
66.90%
Earnings growth
--
Dividend yield
0.00%
Financial statements
| 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|---|
| Revenue | $1.29B | $1.17B | $1.10B | $1.25B | $773.69M |
| Gross profit | $992.50M | $956.05M | $829.31M | $1.05B | $630.74M |
| Operating income | $231.44M | $268.64M | $131.72M | $367.98M | -$16.20M |
| Net income | $164.49M | $205.99M | $186.42M | $251.08M | -$72.23M |
| Basic EPS | 1.23 | 1.55 | 0.84 | 1.91 | -0.55 |
| Diluted EPS | 1.21 | 1.51 | 0.82 | 1.84 | -0.55 |
Estimates vs actuals
Next earnings
2026-10-29
EPS estimate
2.25
Revenue estimate
$1.43B
Last surprise
-14.21%
| Date | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-10-29 | 2.25 | Not reported | — |
| 2026-07-30 | 2.14 | 1.84 | -14.21% |
| 2026-04-30 | 1.47 | 1.99 | +35.30% |
| 2026-02-12 | 1.50 | 1.25 | -16.50% |
| 2025-10-30 | 1.75 | 2.90 | +66.12% |
| 2025-07-31 | 0.15 | 0.32 | +119.58% |
| 2025-05-01 | -0.37 | -0.01 | +97.29% |
| 2025-02-13 | -0.14 | 0.06 | +142.52% |
| 2024-10-31 | -0.39 | -0.50 | -26.71% |
| 2024-08-01 | -0.69 | 0.56 | +181.07% |
| 2024-05-02 | -0.63 | -0.16 | +74.50% |
| 2024-02-15 | -0.77 | -0.77 | -0.20% |
Institutional holders
| Institution | Quarter | Value held | Portfolio weight |
|---|---|---|---|
| VANGUARD GROUP INC | 2025-12-31 | $5.4B | 0.08% |
| BlackRock Inc. | 2024-06-30 | $2.3B | 0.05% |
| STATE STREET CORP | 2026-06-30 | $1.1B | 0.03% |
| TWO SIGMA INVESTMENTS, LP | 2026-06-30 | $564.7M | 0.41% |
| CITADEL ADVISORS LLC | 2026-06-30 | $57.5M | 0.01% |
| Bridgewater Associates, LP | 2026-06-30 | $30M | 0.12% |
13F quarterly filings. Reporting periods differ by institution; value and weight reflect each institution's own latest quarter.
Analyst ratings
Mean target
$367.78
Target range
$250.00 – $536.00
Implied upside
64.16%
Strong buy
6
Buy
17
Hold
7
Sell
0
Strong sell
0
Advertisement